Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Nature
.
2021 Feb;590(7844):E26.
doi: 10.1038/s41586-020-03098-3.
Authors
Mark J Mulligan
#
1
2
,
Kirsten E Lyke
#
3
,
Nicholas Kitchin
#
4
,
Judith Absalon
5
,
Alejandra Gurtman
6
,
Stephen Lockhart
4
,
Kathleen Neuzil
3
,
Vanessa Raabe
1
2
,
Ruth Bailey
4
,
Kena A Swanson
6
,
Ping Li
7
,
Kenneth Koury
6
,
Warren Kalina
6
,
David Cooper
6
,
Camila Fontes-Garfias
8
,
Pei-Yong Shi
8
,
Özlem Türeci
9
,
Kristin R Tompkins
6
,
Edward E Walsh
10
11
,
Robert Frenck
12
,
Ann R Falsey
10
11
,
Philip R Dormitzer
6
,
William C Gruber
6
,
Uğur Şahin
9
,
Kathrin U Jansen
6
Affiliations
1
New York University Langone Vaccine Center, New York, NY, USA.
2
New York University Grossman School of Medicine, New York, NY, USA.
3
University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD, USA.
4
Vaccine Research and Development, Pfizer Inc, Hurley, UK.
5
Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA. judith.absalon@pfizer.com.
6
Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
7
Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.
8
University of Texas Medical Branch, Galveston, TX, USA.
9
BioNTech, Mainz, Germany.
10
University of Rochester, Rochester, NY, USA.
11
Rochester General Hospital, Rochester, NY, USA.
12
Cincinnati Children's Hospital, Cincinnati, OH, USA.
#
Contributed equally.
PMID:
33469216
DOI:
10.1038/s41586-020-03098-3
No abstract available
Publication types
Published Erratum